Projects per year
Abstract
A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated targets. Matthew Lloyd from the University of Bath explains why these hits can arise during drug discovery and how machine learning could be the answer to identifying these compounds.
Original language | English |
---|---|
Pages | 42-44 |
Number of pages | 3 |
Volume | 8 |
No. | 2 |
Specialist publication | Drug Target Review |
Publication status | Published - 7 Jun 2021 |
Fingerprint
Dive into the research topics of 'Why some screening hits are a PAIN'. Together they form a unique fingerprint.Projects
- 2 Finished
-
AMACR Targeted Drugs for Treating Advance Prostate Cancer
Lloyd, M. (PI), James, T. (CoI), Jevglevskis, M. (CoI), Nathubhai, A. (CoI), Threadgill, M. (CoI) & Woodman, T. (CoI)
1/02/15 → 30/07/18
Project: UK charity
-
Targeting AMACR to Treat Castrate Resistant Prostate Cancer
Lloyd, M. (PI) & Woodman, T. (CoI)
5/10/11 → 31/01/15
Project: UK charity